乳腺癌内分泌治疗伴随疾病之代谢相关脂肪性肝病的防治研究进展  

Research Progress of the Prevention and Treatment of Metabolic Associated Fatty Liver Disease as a Complication Disease of Endocrine Therapy for Breast Cancer

作　　者：覃胜鹏 邹全庆[2] 

机构地区：[1]右江民族医学院临床医学院,广西 百色 [2]广西壮族自治区人民医院乳腺外科,广西 南宁

出　　处：《临床医学进展》2025年第3期581-590,共10页Advances in Clinical Medicine

基　　金：广西自然科学基金项目(2024JJA140360)。

摘　　要：乳腺癌是女性最常见的恶性肿瘤,治疗方式除传统手术、放疗和化疗外,内分泌治疗也是乳腺癌综合治疗的重要手段。通常内分泌治疗周期较长,容易导致机体代谢紊乱,诱发脂肪性肝病。代谢相关脂肪性肝病(MAFLD)的发病率逐年攀升,现已成为全球最常见的慢性肝病,同时也是乳腺癌内分泌治疗随访期间常见的并发症之一,不仅可能引起慢性肝损伤和肝纤维化,严重时甚至发展为肝硬化和肝癌,对患者的生活质量和预后造成显著的负面影响。然而,目前对乳腺癌群体中MAFLD的认识和防治尚未引起重视。本文旨在阐述乳腺癌内分泌治疗并发症之一,即MAFLD的防治研究进展,包括其发病因素、诊断方式及防治策略,以期加强该类疾病的早期预防与精准诊治,达到进一步提高患者的生活质量并改善预后的目标。Breast cancer is the most common malignant tumor in women. In addition to traditional surgery, radiotherapy and chemotherapy, endocrine therapy is also an important means of comprehensive treatment for breast cancer. However, endocrine therapy usually has a long duration, leading to metabolic disorders and increasing the risk of fatty liver disease. The incidence of metabolic-associated fatty liver disease (MAFLD) is rising annually, which has become one of the most common chronic liver diseases globally. It is also a common complication during the follow-up of endocrine therapy for breast cancer. MAFLD can not only cause chronic liver injury and liver fibrosis, but in severe cases, it may even progress to liver cirrhosis and liver cancer, significantly and negatively impacting patients’ quality of life and prognosis. Nevertheless, currently, the awareness and prevention-treatment measures for MAFLD in the breast cancer population have not received sufficient attention. The aim of this review is to clarify the advancements in the prevention and treatment of MAFLD, one of the complications of breast cancer endocrine

关 键 词：乳腺癌 内分泌治疗 代谢相关脂肪性肝病 雌激素 

分 类 号：R737.9[医药卫生—肿瘤]